TG Therapeutics Inc. (NASDAQ:TGTX) – Investment analysts at FBR & Co upped their FY2017 earnings per share estimates for shares of TG Therapeutics in a research note issued to investors on Thursday. FBR & Co analyst E. White now anticipates that the brokerage will earn ($1.16) per share for the year, up from their previous estimate of ($1.25). FBR & Co has a “Buy” rating on the stock. FBR & Co also issued estimates for TG Therapeutics’ FY2018 earnings at ($1.41) EPS.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. TG Therapeutics had a negative net margin of 40,142.11% and a negative return on equity of 58.77%.

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

TGTX has been the subject of several other research reports. S&P Equity Research cut their price target on TG Therapeutics from $7.15 to $6.40 in a research note on Wednesday, August 24th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective (down previously from $22.00) on shares of TG Therapeutics in a report on Saturday. Brean Capital reaffirmed a “buy” rating and set a $28.00 price objective on shares of TG Therapeutics in a report on Thursday, October 6th. Roth Capital reaffirmed a “buy” rating and set a $33.00 price objective on shares of TG Therapeutics in a report on Wednesday, August 10th. Finally, Zacks Investment Research lowered TG Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 14th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $21.21.

TG Therapeutics (NASDAQ:TGTX) opened at 6.59 on Monday. The stock’s market capitalization is $358.87 million. TG Therapeutics has a 12 month low of $5.41 and a 12 month high of $14.87. The company has a 50 day moving average of $7.39 and a 200 day moving average of $7.37.

A number of hedge funds have recently bought and sold shares of TGTX. BlackRock Advisors LLC raised its stake in TG Therapeutics by 14.5% in the second quarter. BlackRock Advisors LLC now owns 18,131 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 2,296 shares during the period. Mariner Wealth Advisors LLC raised its stake in TG Therapeutics by 1.4% in the first quarter. Mariner Wealth Advisors LLC now owns 18,286 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 255 shares during the period. SECOR Capital Advisors LP purchased a new stake in TG Therapeutics during the second quarter valued at $187,000. Emerald Acquisition Ltd. purchased a new stake in TG Therapeutics during the second quarter valued at $190,000. Finally, Rhumbline Advisers raised its stake in TG Therapeutics by 9.0% in the second quarter. Rhumbline Advisers now owns 37,547 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 3,107 shares during the period. 54.66% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

5 Day Chart for NASDAQ:TGTX

Receive News & Stock Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related stocks with our FREE daily email newsletter.